Testing a new cancer treatment for advanced or hard-to-treat cancers

Plain-English translation of NCT06999187 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called for people with advanced or hard-to-treat cancers that have not responded to previous treatments. The study will test different doses of the medication to find the safest and most effective level. Researchers will monitor how well the treatment works and what side effects occur.

Many people with advanced cancers run out of standard treatment options after their cancer stops responding to previous therapies. This medication is being studied to see if it can help patients whose cancers have become resistant to other treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with an advanced or hard-to-treat cancer (such as breast, lung, cervical, prostate, pancreatic, head and neck, endometrial, ovarian, stomach, or bladder cancer) that cannot be surgically removed
your cancer has come back or stopped responding to treatment after you've received at least two prior cancer therapies
you have measurable disease that can be seen on imaging scans
you are in good enough overall health to participate, with a life expectancy of at least three months
your heart, kidney, and liver function are adequate as confirmed by blood tests
you are willing to provide a tumor tissue sample for research purposes

You likely don't qualify if…

you have had major surgery within the past four weeks
you have untreated or symptomatic cancer that has spread to your brain
you have received cancer treatment within the required washout period before starting the study
you have an abnormal heart rhythm (QT prolongation) or uncontrolled heart disease
you have a history of stroke, seizures, or other serious neurological conditions

What participation looks like

You will receive the medication as an injection or infusion every two weeks at the clinic. The study starts with lower doses and gradually increases to find the right level, depending on how your body tolerates the treatment. You will continue receiving the medication until your cancer progresses, you experience intolerable side effects, or you choose to withdraw. Throughout the trial, you will have regular visits for blood tests, imaging scans, and check-ins with the research team.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(10 sites)

United States

Dren Investigational Site, Denver, Colorado

Dren Investigational Site, Orlando, Florida

Dren Investigational Site, Sarasota, Florida

Dren Investigational Site, Huntersville, North Carolina

Dren Investigational Site, Oklahoma City, Oklahoma